Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations

Analysts at Topeka Capital initiated coverage on shares of Albemarle (NYSE: ALB) with a “hold” rating. The target price for Albemarle is set to $67. Albemarle's shares closed at $61.88 yesterday.

Oppenheimer initiated coverage on shares of Insys Therapeutics (NASDAQ: INSY) with an “outperform” rating. The target price for Insys Therapeutics is set to $23. Insys Therapeutics's stock closed at $16.05 yesterday.

SunTrust Robinson Humphrey initiated coverage on shares of Goodrich Petroleum (NYSE: GDP) with a “buy” rating. The target price for Goodrich Petroleum is set to $25. Goodrich Petroleum's shares closed at $17.97 yesterday.

Analysts at Credit Suisse initiated coverage on shares of Sunesis Pharmaceuticals (NASDAQ: SNSS) with a “buy” rating. The target price for Sunesis Pharmaceuticals is set to $25. Sunesis's shares closed at $5.40 yesterday.

Latest Ratings for ALB

DateFirmActionFromTo
Aug 2019MaintainsUnderweight
Aug 2019ReiteratesBuy
Aug 2019MaintainsOutperform

View More Analyst Ratings for ALB
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (ALB + GDP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
XELMaintains60.0
SOMaintains54.0
SREMaintains141.0
EXCMaintains56.0
ESMaintains77.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Morgan Stanley Resumes Coverage on Liberty Global at Overweight on Share Gains Forecast

UPDATE: Jefferies Downgrades Optimer Pharmaceuticals Following CBST Sale Announcement